Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Prostatic Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Melanoma 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Ovarian Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Solid Tumor 1Sarcoma, Synovial 1

Interventions

tremelimumab 1durvalumab 1Liver Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hypertension, Portal × tremelimumab × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡